
Minhua Chu/LinkedIn
Aug 28, 2025, 14:03
Minhua Chu: Shenzhen Pregene Biopharma Received FDA Orphan Drug Designation
Minhua Chu, Managing Partner at TransitionValue Partner, shared a post on X:
“Shenzhen Pregene Biopharma has received Orphan Drug Designation (ODD) from the FDA for its CD19/CD22-targeted CAR-T therapy for the treatment of acute lymphoblastic leukemia (ALL).
Pregene’s CD19/CD22-targeted CAR-T therapy is in preclinical stage. It is currently undergoing an Investigator-Initiated Trial (IIT) in collaboration with a Chinese hospital.
Results show that all six patients receiving the CAR-T therapy for the first time achieved complete remission (CR), with an objective response rate (ORR) of 100% and a minimal residual disease (MRD) negativity rate of 100%.”
More posts featuring Minhua Chu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 28, 2025, 14:03
Aug 28, 2025, 13:48
Aug 28, 2025, 13:40
Aug 28, 2025, 13:36
Aug 28, 2025, 13:19
Aug 28, 2025, 13:13
Aug 28, 2025, 12:37
Aug 28, 2025, 12:32
Aug 28, 2025, 12:30